Beximco Pharmaceuticals Ltd Stock Dividend Issued and Total Voting Rights (5965R)

TIDMBXP

RNS Number : 5965R

Beximco Pharmaceuticals Ltd

12 December 2016

12 December, 2016

BEXIMCO PHARMACEUTICALS LTD.

Stock Dividend Issued and Total Voting Rights

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the stock dividend proposed on 20 April, 2016 and passed by shareholders at the Annual General Meeting ("AGM") on 19 November, 2016 has been credited to shareholder accounts. Please note that the stock dividend was proposed in the Board meeting held on 20 April, 2016.

The Company has applied for the admission of 4,330,648 new Global Depositary Receipts ("GDRs") issued in respect of the stock dividend to be admitted to trading on AIM and admission is expected to occur at 8:00 am on 19 December, 2016 ("Admission").

Following Admission, the total issued share capital of the Company will be 405,556,445 ordinary shares of Taka 10 ("Ordinary Shares"), of which 90,943,627 will be represented by GDRs, each representing one Ordinary Share. The new Ordinary Shares will rank pari passu in all respects with the existing issued Ordinary Shares, all having voting rights.

Shareholders in the Company may use the number of 405,556,445 Ordinary Shares to calculate their reporting obligations under DTR 5.

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: [phone], ext.20080

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel: [phone], ext.10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Sean Wyndham-Quin

Tel: [phone] / 3555

Daniel Stewart & Company plc (Broker)

David Lawman / Daphne Zhang

Tel: [phone]

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: [phone]

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebuliser solutions and oral soluble films. Ensuring access to quality medicines is the powerful aspiration that motivates 3,500 employees of the Company.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of the US, Europe, Australia, Canada, GCC and Latin America, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in South East Asia, including Singapore, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong; Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central Asia, including Azerbaijan; Middle East, including Kuwait and Jordan; Pacific Island countries; Latin and Central American countries; Europe, including Austria, Germany and Romania; Australia and the US.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCFFEFDEFMSEDE

(END) Dow Jones Newswires

December 12, 2016 08:54 ET (13:54 GMT)